Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Gothenburg, February 7, 2023 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, today announced that it has recruited LifeSci Consulting as transaction advisor to assist the company in evaluating a variety of strategic partnering initiatives.
Elicera’s collaboration with LifeSci Consulting is a long-term investment that follows an increase in third-party interest to initiate potential collaboration dialogues with Elicera around its iTANK platform and certain programs under development.
“We are pleased to have seen interest in collaborations rise after proof-of-concept data for the iTANK platform was published in Nature Biomedical Engineering last year. Securing licensing agreements and a variety of collaborations for iTANK is an essential part of Elicera’s business strategy and we believe it is in our shareholders’ best interest that the company explore different partnering options together with a leading life science transaction advisory firm such as LifeSci Consulting. While completion of any transactions is not assured, we look forward to beginning our collaboration with LifeSci Consulting and exploring different partnering alternatives together with them,” says Jamal El-Mosleh, CEO of Elicera Therapeutics.
“Elicera is developing state-of-the-art technology to solve immune challenges in the oncology space and Elicera’s next generation iTANK platform and ongoing programs have the potential to take us to the next frontier of cancer treatment. This collaboration will accelerate Elicera’s ability to find optimal partners to generate long-term value for patients and shareholders. With 5,000+ global industry contacts and $8B total deal value, our team is ideally positioned to provide Elicera with impactful strategic counsel to support optimum strategic transactions. We are impressed by the leadership and expertise at Elicera and look forward to our exciting journey ahead”, said Cristiano Musso, Partner, Head of Europe of LifeSci Consulting.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Adviser:
Erik Penser Bank
About LifeSci Consulting
LifeSci Consulting is a leading life sciences strategy consulting and transaction advisory firm. The firm leverages deep scientific acumen to assess commercial potential and positioning as well as to inform commercial strategy and market access. The firm’s transaction advisory practice focuses on securing non-dilutive capital and assets for clients through buy-side and sell-side strategic partnering transactions. For more information, please visit https://www.lifesciconsulting.com
About the iTANK platform
The iTANK- (immunoTherapies Activated with NAP for efficient Killing) technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to arm the company's own CAR T-cells but can also be universally applied to other CAR/TCR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK-platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next-generation therapies based on oncolytic viruses and CAR T-cells, armed with the company’s proprietary and commercially available platform, iTANK. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. The iTANK-platform is used to arm the company's own CAR T-cells, in addition to the oncolytic virus ELC-201, but can also be universally applied to other CAR/TCR T-cell therapies under development. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit www.elicera.com